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1. Introduction 
The World Health Organization calculates that over – six hundred and fifty million people 
worldwide suffer of some form of liver disease, including thirty million Americans. On a 
worldwide base, approximately one to two million deaths are accounted to liver related 
diseases annually. Around the globe, China has the world’s largest population of Hepatitis 
B patients (approx. 120 million) with five hundred thousand people dying of liver illnesses 
every year (CDC, 2007; WHO, 2008). In the US alone, five hundred thousand critical liver 
problem episodes are reported every year requiring hospitalization with great burden to the 
patients and a huge cost to the health care system. In the European Union and United States 
of America alone, over eighty one thousand and twenty six thousand people died of chronic 
liver disease in 2006, respectively (CDC, 2007; Eurostat, 2007). In these patients, liver 
transplantation is presently the only proven therapy able to extend survival for end-stage 
liver disease. It is also the only treatment for severe acute liver failure and to some forms of 
inborn errors of metabolism. 
The road to successful liver grafting in humans has been long and fraught with many 
obstacles. Experimental attempts at liver transplantation originally took place in the 1950s 
and 1960s, but human liver transplantation did not become a reality until 1963 (Starzl & 
Demetris, 1990). Although unsuccessful, Dr. Starzl's attempt at liver transplantation was a 
milestone in surgery. However, it took nearly 20 years to develop a surgical procedure for 
orthotopic liver transplantation (OLT) that was safe to apply in humans. In 1983, the 
National Institutes of Health (NIH) held the Consensus Development Conference on Liver 
Transplantation. The most important outcome of this conference was OLT became an 
accepted therapeutic modality for some patients with end-stage liver disease (NIH, 1983). 
The ideal liver transplant candidate needed to comply with ten conditions (Table 1) as well 
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as ten absolute contraindications and five relative contraindications (Table 2). Taking into 
account the multitude of criteria for OLT, few patients were deemed eligible. Furthermore, 
the University of Pittsburgh was the only liver transplant center in the United States in 1983. 
Currently, 120 liver transplant centers in the United States are registered with the United 
Network for Organ Sharing (UNOS), the organization that manages the nation's organ 
transplant system, and 145 transplant centers from 24 European countries are participating 
in the European Liver Transplant Registry (ELTR). As reported in the UNOS database, 
111,824 liver transplantations have been performed in the United States through December 
2010 (UNOS, 2010). Likewise, 100,542 liver transplantations have been performed in Europe 
with an average of 5,562 transplantations per year in the past decade (ELTR, 2010).  
 
 
Young patient < 50 years
No viral infection 
No alcohol or drug abuse 
Normal vessel state 
No infection 
No (advanced) malignancy 
No cardiopulmonary or renal disease 
No prior abdominal surgery 
Ability to accept the procedure or understand its nature 
Ability to accept costs of the procedure
Table 1. The ten conditions to be an ideal liver transplant candidate at the 1984 NIH 
Consensus Conference 
 
 
ABSOLUTE 
Portal vein thrombosis 
Severe hypoxemia due to right to left shunts (HPS) 
Sepsis outside the hepatobiliary (HB) system 
Primary malignant disease outside the HB system 
Metastatic HB malignancy 
Active alcoholism 
Advanced cardiopulmonary or renal disease 
HBsAg and HBeAg positive state 
Age > 55 years 
Inability to accept the procedure or understand its nature and/or its costs 
RELATIVE  
Intrahepatic or biliary sepsis 
Advanced alcoholic liver disease in the abstinent alcoholic 
Age > 50 years 
HBsAg positive state 
Prior abdominal surgery especially in the right upper quadrant 
Portal hypertension surgery
Table 2. The ten absolute and five relative contraindications to liver transplantation at the 
1984 NIH Consensus Conference 
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Since the first OLT was performed, the field has changed dramatically. Improvements in 
surgery, anaesthesia, immunosuppression, and control of infection have translated into 
increased access and better patient outcomes.  In the pioneering days of OLT, triple-drug 
therapy (corticosteroids, azathioprine [AZA], and antilymphocyte globulin [ALG]) was used 
to prevent and treat rejection. The development of a powerful immunosuppressive agent, 
cyclosporine (CsA), in the late 1970s was one of the most significant events in modern 
transplantation. By 1984, all transplant centers in the United States used double therapy of 
corticosteroids and CsA as the maintenance immunosuppressive regimen. During the 1990s, 
tacrolimus (TAC) emerged as the mainstay maintenance immunosuppressive agent in OLT, 
with or without corticosteroids. More recently, mycophenolate mofetil (MMF) has replaced 
the use of AZA in many centers. Before the advent of CsA, 5-year survival after OLT was 
less than 20%. Current survival rates 1, 3, and 5 years after liver transplantation in the 
United States are 88%, 80%, and 75%, respectively (UNOS, 2010).  
Advancements in surgical techniques and technologies also account for the increased 
success of OLT. In particular, the standardization of biliary tract reconstruction, advances in 
retransplantation, and improvements in surgical technology help explain better patient 
outcomes.  Examples of developments in technology include pump-driven veno-venous 
bypass that does not require recipient heparinization, rapid infusion, and autologous auto-
transfusion devices. Additionally, improved procurement and preservation techniques for 
the donor liver and increased insight into the management of potentially fatal complications 
have led to improved patient morbidity and mortality. 
2. Evolution of liver transplant indications 
Nowadays, liver transplantation is indicated for acute or chronic liver failure of any cause 
(Table 3).  
Cirrhosis due to chronic hepatitis C infection is one of the most common indications for liver 
transplantation in the United States and Europe. Despite effective antiviral treatments 
including Pegylated Interferon, Ribavirin, and direct-acting antiviral agents (DAAs), this 
indication is likely to remain important for the coming decades given the large prevalence of 
chronic hepatitis C infection and the propensity of the disease to lead to cirrhosis and 
hepatocellular carcinoma (HCC) (Merion, 2010). 
Chronic hepatitis B has become a less common indication, mostly due to the advent of 
universal vaccination. Additionally, dramatic improvements in the treatment of hepatitis B, 
such as the development of nucleoside/nucleotide analogues, has reduced the number of 
patients with chronic hepatitis B progressing to end-stage liver disease.  However, in parts 
of the world where chronic hepatitis B is endemic, including much of Asia, this remains the 
most common indication (Perrillo, 2009). 
Alcohol-related liver disease is an important indication for OLT in Western countries and is 
oftentimes associated with concomitant hepatitis C infection. In the past, patients with 
alcohol-related liver disease and alcohol dependence were often refused access to liver 
transplantation due to unjust societal allocation of scarce donor organs. However, a careful 
assessment with the support of a health care professional experienced in the management of 
patients with addictive behavior is associated with low rates of recidivism after OLT (Lucey, 
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1992). Nowadays, this indication has become more commonly accepted, as long as patients 
demonstrate sobriety of at least 6 months duration. 
 
Year of Transplant 
Primary 
Diagnosis 
1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 
Total 4,424 4,498 4,595 4,673 4,969 5,351 5,847 6,120 6,362 6,223 
Noncholestatic 
cirrhosis 
2,790 2,899 2,956 2,973 3,091 3,151 3,514 3,709 3,732 3,547 
Cholestatic 
liver disease 
563 499 475 471 492 513 510 467 552 555 
Acute hepatic 
necrosis 
349 405 436 366 369 355 425 448 371 368 
Biliary atresia 214 188 161 172 164 175 187 179 143 174 
Metabolic liver 
disease 
163 152 165 170 152 183 180 200 215 175 
Malignant 
neoplasm 
98 87 84 142 3311 371 481 610 774 783 
Other 247 258 318 378 370 603 550 507 575 608 
a 2008 Annual Report of the U.S. Organ Procurement and Transplantation Network and the Scientific 
Registry for Transplant Recipients: Transplant Data 1998–2007. Rockville, MD: U.S. Department of 
Health and Human Services, Health Resources and Services Administration, Healthcare Systems 
Bureau, Division of Transplantation; 2009 
Table 3. Primary Diagnosis of Deceased Donor Liver Transplant Recipients, 1998 to 2007a 
Cholestatic liver disease is becoming an increasingly uncommon indication for OLT. Data 
from UNOS show that among cadaveric liver transplants in 1991, 18% were for cholestatic 
liver disease, compared with 10% in 2000 and only 7.8% in 2008 (UNOS, 2010). The 
incidence and prevalence of primary biliary cirrhosis (PBC) are steadily increasing whereas 
the absolute number of OLT performed for PBC is falling (UNOS, 2010; ELTR, 2010). 
Reasons for this decline in the number of transplants for PBC are not clear but may relate to 
a changing pattern of disease, increased rates of diagnosis, and more effective treatment. 
The number of transplants for primary sclerosing cholangitis (PSC) in western countries 
during the period 1995-2006 has remained stable and represents 8% of all liver transplants. 
In some areas that have a relatively low prevalence of hepatitis C and alcoholic liver disease 
(ALD), such as the Scandinavian countries, PSC is the leading indication for OLT, 
accounting for 16% of the indications (Nordic Liver Transplant Registry, 2010). 
Nonalcoholic fatty liver disease (NAFLD) is becoming one of the most common liver 
disorders in developed countries. Because this disorder can lead to cirrhosis in a number of 
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patients and is associated with an increased risk of hepatocellular carcinoma (HCC), it is an 
increasingly frequent indication for liver transplantation (Burke, 2004). Considering the 
current obesity epidemic, NAFLD may become the most common indication for liver 
transplantation in the coming years. 
Primary HCC is a unique and evolving indication for liver transplant. Initially, outcomes in 
liver transplantations for patients with unresectable HCC were not encouraging. Ninety 
percent of those transplanted for HCC developed recurrent disease within 2 years.  As a 
result, HCC was considered a contraindication to transplantation for a number of years. 
Ongoing research on HCC post-transplant elucidated that important predictors of 
recurrence are tumor characteristics, such as tumor size, stage, and grade, number of 
nodules, micro- or macrovascular invasion, serum levels of alpha-fetoprotein, and 
demonstrated absence of extrahepatic spread. In 1996, Mazzaferro and colleagues defined 
the Milan criteria, which require a single tumor ≤ 5 cm in diameter or no more than three 
tumor nodules, each ≤ 3 cm in diameter. Liver transplant in patients meeting the Milan 
criteria have excellent outcomes and low recurrence rates (Mazzaferro, 1996). 
Augmentations to the Milan criteria are currently being debated in the liver transplant 
community. The San Francisco criteria, which require either a single lesion ≤ 6.5 cm or up to 
three lesions none of which is >4.5 cm and with total tumor diameter ≤ 8 cm, have been widely 
debated, but no consensus has yet emerged (Yao, 2001). Finally, more attention has been given 
to the role of downstaging by locoregional therapy for otherwise unsuitable candidates. 
Treatments to shrink nodules, including radiofrequency ablation, transcatheter arterial 
chemoembolization, and novel thermal and non-thermal techniques for tumor ablation offer 
strategies for subsequent transplantation in patients with more advanced lesions.  
Many inborn errors of metabolism have been successfully treated with liver transplantation 
(Kayler, 2003). 
Acute liver failure has long been considered an appropriate indication for liver transplant. 
Patients with fulminant hepatic failure should be referred to a transplant center as quickly 
as possible for critical care management. If given appropriate critical care support, many 
patients spontaneously recover. Patients predicted to have little chance of spontaneous 
recovery should undergo transplantation as soon as possible. New technologies using 
bioartificial liver devices including both a biological component and an artificial scaffold 
may offer some promises for patients with acute liver failure. However, these technologies 
have not become widely available yet, and therefore OLT remains an important treatment 
(Demetriou, 2004; Ellis, 1996). 
3. Historical contraindications to OLT 
3.1 Absolute contraindications 
3.1.1 Splanchnic venous thrombosis 
Splanchnic venous thrombosis and portal hypertension surgery are both part of the natural 
evolution of cirrhosis. Intra-operative mortality during OLT with these conditions was once 
nearly 50%. Those that survived OLT oftentimes had morbid conditions that diminished the 
utility of the transplant. In recent times, several technical advances have been made to 
overcome this problem. Eversion thrombectomy is a good treatment option for a majority of 
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patients with splanchnic venous thrombosis. If eversion thrombectomy is not possible, a free 
iliac interposition graft between the allograft portal vein and the superior mesenteric vein is 
indicated. Sometimes it is possible to connect the allograft portal vein to a collateral vein. In 
cases of extended splanchnic thrombosis, cavo-portal hemi-transposition or combined liver-
intestinal transplantation are the last resorts for treatment (Lerut, 1997). 
3.1.2 Hepatopulmonary Syndrome (HPS) 
HPS is defined as a pO2 < 70 mmHg in an upright position. It is present in up to 20% of 
cirrhotic patients. Even in cases where oxygen saturation is below 50 mmHg, this situation 
can be reversed by a successful OLT. The post-transplant recovery is usually more 
complicated necessitating adapted respiratory care. The pre-transplant baseline macro-
aggregated albumin shunt fraction may indicate the limits of correction following OLT 
(Starzl, 1990). 
3.1.3 Sepsis outside the hepatobiliary system 
Active extra-hepatic infection compromises outcomes of OLT. Nonetheless, transplantation 
can be performed successfully if the infection is confined to the lungs or the ascites and does 
not cause hemodynamic instability (Starzl, 1990). Post-transplant care is usually much more 
prolonged and expensive if the patient has sepsis outside the hepatobiliary system. 
3.1.4 Primary malignant disease outside the hepatobiliary system 
Based on the embryological development theory, Starzl advocated the ‘en block’ or ‘cluster 
transplant’ in order to treat extended hepatobiliary malignancies and liver metastases from 
neuroendocrine tumors. Although initial success was promising, longterm results were 
disappointing. (Lerut, 2007, 2011; Starzl, 1990). 
Pre-OLT malignancies or malignancies discovered incidentally during the OLT-procedure 
are no longer contraindications to OLT as shown by the Kings’ College study. Metastatic 
hepatobiliary malignancy is an emerging indication for OLT. After successful 
chemotherapeutic treatment of hepatic and thoracic tumor involvement in children with 
hepatoblastoma, excellent results have been obtained with OLT. Similarly, excellent 
longterm results have been obtained for epithelioid hemangio-endothelioma. In the latter 
group some centers propose sequential or simultaneous hepatopulmonary transplantation 
(Lerut, 2007). 
The role of OLT in the treatment of neuroendocrine tumors with hepatic involvement is 
continuously evolving. Excellent OLT results can be obtained in select, young (<50 years) 
patients after R0 resection of the primary tumor for more than six months prior to 
transplant. Furthermore, if the primary lesion has favorable tumor biology (as expressed by 
a Ki67 index of < 5-10%) and has a portal vein drainage, results are significantly improved 
(Bonaccorsi-Riani, 2010). 
It is evident that all oncologic patients that undergo OLT will benefit from adapted 
immunosuppression. Minimization of immunosuppression and use of the m-TOR inhibitor, 
rapamycin, are of paramount importance. Rapamycin has antitumor activity based on 
antiangiogenic properties. 
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The most recent development in the field of OLT is the treatment of metastatic colorectal 
malignancy. The Oslo-SECA (SEcondary CAncer) study indicates that OLT will have a role 
in the treatment of colorectal metastases on the condition that adapted chemotherapy and 
immunosuppression are employed after the transplant procedure. Preliminary results 
obtained in the Oslo-SECA cases show nearly 50% 5-year survival after OLT (Foss, 2011). 
3.1.5 Alcohol abuse 
OLT in active alcoholic patients has always been discussed heavily within the medical 
community (Starzl, 1990). The ‘six month abstinence rule’ is not generally enforced, and 
some French groups even advocate OLT in cases of severe acute alcoholic hepatitis 
(Mathuri, 2005).  
3.1.6 Drug abuse 
Although also heavily debated, some groups in New York showed that OLT can be 
successful in recipients on methadone maintenance. 
Both alcohol and drug abusers need exceptionally tight follow-up during the pre- and post-
transplant period. It is of utmost importance to take familial, professional, and social 
conditions into consideration in these potential patients (Starzl, 1990). 
3.1.7 Advanced cardiopulmonary disease 
Two-staged cardiac and hepatic transplantion is becoming more frequent (Starzl, 1990). 
Several case reports have been published about simultaneous liver and heart transplantation 
in the context of familial amyloid polyneuropathy (FAP) and hemochromatosis. 
Simultaneous OLT with coronary, valvular, or arrythmia surgery has also been reported. 
These surgeries are complex and have stimulated major interest in both cardiovascular and 
hepatic experts of transplant centers. 
3.1.8 Viral infections 
Viral cirrhosis was once an absolute contraindication to OLT because of the universal 
recurrence of the disease in the liver allograft (Lerut, 1998).  The landmark paper of Samuel 
in 1993 showed that adequate antiviral prophylaxis using specific anti-HBs antibodies 
protects the allograft from reinfection (Samuel, 1993). Further improvement has been 
achieved by combining nucleoside and nucleotide analogues with immunoglobulins. This 
prophylactic combination was able to reduce the incidence of allograft reinfection from 
100% to 5%. Moreover, those with HBV gain an immunologic advantage from 
immunoglobulin treatment due to immunoglobulins producing a tolerogenic effect on 
dendritic cells. 
3.1.9 Age 
Increasing numbers of transplants are done in patients aged over 65 and 70 years of age 
(Starzl, 1990). The initial Pittsburgh results have now been confirmed by most transplant 
centers. 
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3.1.10 Inability to accept or understand the procedure 
OLT is accessible to patients in all levels of society. Successful OLT has been reported in 
Down Syndrome patients and in drug abusers. Adequate preparation by medical, 
paramedical, and clinical coordinator teams is of utmost importance in complicated clinical 
scenarios. 
3.2 Relative contraindications 
3.2.1 Intra-hepatic or biliary sepsis 
Chronic biliary infection is frequent in Caroli disease, primary sclerosing cholangitis, and 
secondary sclerosing cholangitis. Because the infection is usually confined to the liver, 
outcome of OLT is excellent as transplantation removes the source of the infection. OLT is 
especially valuable in these patients as it dramatically improves their quality of life. 
3.2.2 Advanced liver disease in abstinent alcoholic patients 
The Model for End-Stage Liver Disease (MELD) scoring system aims to reduce liver waitlist 
mortality by transplanting sicker patients more rapidly. Abstinent alcoholics frequently 
belong to the sickest patient groups. Nowadays, OLT is a very good indication in such 
patients if the recipient remains abstinent and is compliant. If the recipient remains 
abstinent, alcoholic cirrhosis is one of the best indications for OLT as this is the only disease 
that does not recur in the allograft.  Moreover, abstinent alcoholics that receive OLT offer a 
unique opportunity to study the effect of immunosuppression withdrawal without primary 
disease involvement in the allograft. 
3.2.3 Previous abdominal surgery 
Many transplant recipients have undergone previous abdominal and right upper quadrant 
surgery. These interventions can compromise the transplant procedure.  Thus, exploratory 
or staging laparotomies as well as unnecessary cholecystectomies and cyst fenestrations 
should be avoided in future OLT patients.  Interventional radiology procedures such as the 
Transjugular Intrahepatic Portosystemic Shunt (TIPSS) are preferred in potential OLT 
recipients instead of portal hypertension surgery. In cases where portal hypertension 
surgery cannot be avoided, meso-caval or spleno-renal shunts are the preferred options 
leaving the hilar region intact. 
3.2.4 HIV infection 
HIV patients that are well controlled on Highly Active Antiretroviral Therapy (HAART) are 
generally not contraindicated for OLT. The indication for OLT relates more so to 
concomitant HCV and/or HBV infection. Co-infected patients are at higher post-OLT 
infectious risk. Particular attention should be given to the interaction between anti-viral 
drugs and calcineurin inhibitors. 
3.2.5 Positive HBsAg status 
See above. 
www.intechopen.com
 
Liver Transplantation in the Clinic – Progress Made During the Last Three Decades 185 
4. Future perspectives 
Criteria for placement on the waiting list have become more quantitative. Continuous 
refinement of the allocation system will improve the management of the waiting list 
(Metsellaar, 2011).  
Alternative techniques such as split liver transplantation (SLT) and living donor liver 
transplantation (LDLT) will allow for expansion of the allograft pools. The bipartition of the 
liver is especially important in pediatric patients for whom size-matched whole liver 
allografts are scarce. Split grafts have been associated with reduction in the risk of death on 
the pediatric waiting list. However, SLT is much less successful in the adult-adult SLT. 
Donor selection for splitting and technical and logistical expertise to decrease total ischemia 
time are important factors in successful transplantation. A better understanding of the liver 
anatomy and improving surgical skills have allowed living liver donation to become a 
routine procedure in some centers. Given the major risks of the operation required for the 
donor, whether this procedure will ever find wide application is unclear. 
As there will always be more potential recipients than donors, many researchers are 
working in the field of artificial tissue engineering and regenerative medicine (RM) 
(Orlando, 2011a, 2011b, 2011c, 2011d, 2012a, 2012b, 2012c). RM holds the promise of 
regenerating tissues and organs by either stimulating previously irreparable tissues to heal 
themselves, by treating liver disease with cell therapies, or by manufacturing tissues ex vivo 
using extracellular matrix (ECM) scaffolds. 
This last approach, uses ECM scaffolds that have an intact but decellularized vascular network 
that is repopulated with autologous or allogeneic stem cells and/or adult cells. Liver ECM 
scaffolds may be produced from humans or animals. In the latter case, human cells are used to 
repopulate a scaffold of animal origin, coining a new concept called semi-xenotransplantation 
(Orlando, 2011a, 2011b). Importantly, preemptive transplantation with regenerated tissues will 
improve outcomes, especially in cases of metabolic and cystic liver disease. 
Future progress in the medical treatment of oncology will enhance outcomes in OLT (Lerut, 
2007, 2011; Bonaccorsi-Riani, 2010, Foss, 2011). As treatments of vascular tumors, advanced 
hepatocellular cancer, cholangiocellular cancer, neuroendocrine tumors, and colorectal liver 
metastases improve, indications for OLT in the 21st century will become more inclusive of 
advanced oncologic disease states. 
Combined organ transplantation is becoming more frequent as many liver diseases are 
accompanied by renal function impairment. Nowadays, 15% of all liver recipients have 
combined liver-kidney transplantation. 
Transplant teams should focus more on late morbidity and mortality. Currently, the majority 
of long-term survivors die from infectious disease, cardiovascular disease, or cancer while 
having a functional graft. This mortality is directly related to the strength of the maintenance 
immunosuppression. Minimization or even withdrawal of immunosuppressive protocols 
must become a priority in organ transplantation (Lerut, 2003, 2008). Unfortunately, tolerance 
protocols are frequently based on a trial and error approach, as good markers to predict 
tolerance are not yet available (Lerut, 2006). As the liver is an immunoprivileged organ with 
relatively high resistance against immune responses, liver recipients should be at the forefront 
of this research. 
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5. Conclusion 
Since the first transplantation was performed much progress has been made in the field of 
OLT. Indications for liver transplant have evolved to include previously contraindicated 
conditions such as those with hepatocellular carcinoma and alcohol-related liver disease. All 
but one (active sepsis outside the biliary system) contraindication to OLT has been 
eliminated.  As a result, more than 200,000 patients have been transplanted, many with 
excellent long-term success. With indications to transplantation increasing and 
contraindications waning, many more patients will be transplanted in the future.  
The future of liver transplantation will be no less challenging for its practitioners. The main 
challenge is the shortage of organs, and many strategies are in place to address this problem. 
In the near future, immunologic discoveries will allow for an immunosuppression-free state 
of many recipients. This will guarantee better quality of life and similar survival expectancy 
as non-transplanted patients. Regenerative medicine technology applied to liver 
transplantation has the potential to meet the two major needs: namely, the identification of a 
potentially inexhaustible source of livers and an immunosuppression-free state. In the ideal 
scenario, livers will be manufactured from autologous cells with no need for anti-rejection 
therapy. 
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